

**Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69)
Recombinant Antibody
Catalog # APR10816****Specification**

Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	Q07108
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) - Additional Information**Target/Specificity**
CD69**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) - Protein Information****Name** CD69**Synonyms** CLEC2C**Function**
Transmembrane protein expressed mainly on T-cells resident in mucosa that plays an essential role in immune cell homeostasis. Rapidly expressed on the surface of platelets, T-lymphocytes and NK cells upon activation by various stimuli, such as antigen recognition or cytokine signaling, stimulates different signaling pathways in different cell types (PubMed:24752896, PubMed:26296369, PubMed:35930205). Negatively regulates Th17 cell differentiation through its carbohydrate dependent interaction with galectin-1/LGALS1 present on immature dendritic cells (PubMed:24752896). Association

of CD69 cytoplasmic tail with the JAK3/STAT5 signaling pathway regulates the transcription of RORgamma/RORC and, consequently, differentiation toward the Th17 lineage (By similarity). Also acts via the S100A8/S100A9 complex present on peripheral blood mononuclear cells to promote the conversion of naive CD4 T-cells into regulatory T-cells (PubMed:26296369). Acts as an oxidized low-density lipoprotein (oxLDL) receptor in CD4 T- lymphocytes and negatively regulates the inflammatory response by inducing the expression of PDCD1 through the activation of NFAT (PubMed:35930205). Participates in adipose tissue-derived mesenchymal stem cells (ASCs)-mediated protection against P.aeruginosa infection. Mechanistically, specifically recognizes P.aeruginosa to promote ERK1 activation, followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) and other inflammatory cytokines secretion (PubMed:34841721). In eosinophils, induces IL-10 production through the ERK1/2 pathway (By similarity). Negatively regulates the chemotactic responses of effector lymphocytes and dendritic cells (DCs) to sphingosine 1 phosphate/S1P by acting as a S1PR1 receptor agonist and facilitating the internalization and degradation of the receptor (PubMed:37039481).

Cellular Location

Cell membrane; Single-pass type II membrane protein


Tissue Location


Expressed on the surface of activated T-cells, B- cells, natural killer cells, neutrophils, eosinophils, epidermal Langerhans cells and platelets

Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) - Images



Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) is more than 95%, determined by SEC-HPLC.